Advertisement: Cambridge Network mid banner
7 April, 2022 - 22:51 By Tony Quested

Nasdaq big hitter joins Mestag as non-exec director

Mestag Therapeutics, a breakthrough inflammatory disease and immuno-oncology company based in Cambridge, has appointed a life science industry heavyweight as a non-executive director.

Dr Ton Logtenberg is the founder and former President and CEO of Merus, a Nasdaq-listed clinical-stage biotechnology company focused on cancer. 

He was also founder and CEO of U-BiSys, a Dutch biotechnology company that merged with Introgene to become Crucell. There he served as chief scientific officer responsible for the discovery and development of vaccines and antibodies. Crucell was acquired by Johnson and Johnson in 2011 for $2.4 billion. 

Together with Dr Hans Cleavers, Dr Logtenberg founded the HUB foundation for organoid technology and served on the board of directors and supervisory board. He is chairman of the board of Synox Therapeutics. 

He said: “Mestag is pioneering an extraordinary new field of biology, focused on the ability of fibroblasts to directly influence immune effector cells and mediate the immune environment.

“I am delighted to be joining this talented and dynamic team and look forward to working with them as they build a pipeline of first-in-class therapies for cancers and inflammatory diseases.” 

Mestag chief executive Susan Hill added: “As a founder of Crucell, Merus and HUB Organoids, Ton has an outstanding background both as a scientist and an entrepreneur. His experience and expertise will further strengthen our board and provide invaluable guidance to Mestag as we continue to progress and expand our portfolio and partnerships.

Newsletter Subscription

Stay informed of the latest news and features